Molecular Insight Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. Piper Jaffray & Co. and SG Cowen & Co., LLC are acting as joint book-running managers for the offering. In addition, Oppenheimer & Co. Inc. and Roth Capital Partners LLC are acting as co-managers.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1101292XSL_NEWSML_TO_NEWSML_WEB.xml)